These are top 10 stocks traded on the Robinhood UK platform in July
On Tuesday, H.C. Wainwright reiterated its Buy rating on Gossamer Bio Inc . (NASDAQ:GOSS) shares, maintaining a $10.00 price target. The stock, currently trading at $1.39, has shown remarkable momentum with a 52.56% gain over the past six months. According to InvestingPro data, analyst targets range from $1.25 to $15, reflecting diverse opinions about the company’s potential. The firm’s analyst highlighted the biopharmaceutical company’s promising future due to its lead asset, seralutinib, an inhaled tyrosine kinase inhibitor (TKI). Seralutinib is currently being developed for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The analyst expressed optimism regarding the drug’s unique mechanism of action, which targets vascular remodeling—a key factor in these diseases—rather than solely providing vasodilation. This approach could potentially establish seralutinib as a best-in-class therapy. While the company maintains a strong financial position with a current ratio of 6.88 and an overall GOOD financial health score according to InvestingPro, investors should note that the company is not yet profitable, with an EBITDA of -$59.09M. The ongoing Phase 3 trial, PROSERA, is expected to deliver pivotal data in the fourth quarter of 2025. Positive outcomes from this trial could significantly impact Gossamer Bio’s market position.
Gossamer Bio’s strategic move to expand into treating PH-ILD has also been identified as an opportunity to significantly increase the company’s value. A registrational Phase 3 program for PH-ILD is anticipated to begin in the second half of 2025, which could further solidify the company’s presence in the pulmonary treatment landscape.
The analyst’s statement underscored the potential for seralutinib to drive long-term value for Gossamer Bio, describing it as a differentiated, disease-modifying therapy in two areas of high medical need. With a market capitalization of $316M and several promising InvestingPro indicators including strong recent performance and solid liquidity metrics, investors seeking detailed analysis can access additional exclusive insights and 8 more ProTips through an InvestingPro subscription. With top-line PAH data expected approximately a year from now and a clear path laid out for PH-ILD treatment, the risk-reward setup for investing in Gossamer Bio at current levels was deemed compelling by H.C. Wainwright.
In other recent news, Gossamer Bio reported fourth-quarter results that exceeded analysts’ expectations. The company posted a loss of $0.15 per share, which was narrower than the anticipated loss of $0.17 per share. Revenue for the quarter reached $9.34 million, surpassing the consensus forecast of $7.02 million. For the full year 2024, Gossamer Bio recorded a net loss of $56.5 million, or $0.25 per share, a significant improvement from the $179.8 million loss, or $1.18 per share, in 2023. The company concluded the year with $294.5 million in cash and marketable securities. Gossamer Bio continues to advance its lead drug candidate seralutinib, with ongoing enrollment in the Phase 3 PROSERA study for pulmonary arterial hypertension. The company plans to start a Phase 3 trial for pulmonary hypertension associated with interstitial lung disease in the second half of 2025. Research and development expenses increased to $36.1 million in the fourth quarter, up from $30 million in the same quarter of the previous year. Gossamer Bio expects its current cash reserves to sustain operations into the first half of 2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.